E-poster
HBV
Rachel Wen-juei Jeng O-012 Influence of AFP level during direct antiviral therapy on HBeAg loss
Rui Zhou P-013 A Model to Estimate Survival in Hepatitis B Virus-Related Acute-on-Chronic Liver Failure Based on Dynamic Changes in Objective Parameters
Ming-Lun Yeh P-016 Efficacy and Safety of Tenofovir Alafenamide in Treatment-Experienced Chronic Hepatitis B patients
Chien-Hung Chen P-017 Comparisons of HBsAg changes and HBsAg loss between HBeAg-negative chronic hepatitis B patients who discontinued entecavir without retreatment and those who continued entecavir therapy
Meng Shu P-018 Hepatocellular Carcinoma among Chronic Hepatitis B patients treated with Nucleotide Analogues in China
Keisuke Ojiro P-019 A patient with HBV reactivation with single codon substitution of S202 and N236 but without resistance mutations during Entecavir therapy
Ming-Te Kuo P-020 Comparison of HBV Relapse Rates between Patients Who Discontinue Entecavir and Tenofovir Disproxil Fumarate Treatment in Chronic Hepatitis B Patients – beyond One Year Follow-Up
Ching-Chung Lin P-021 High percentage atypical hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogues
Tung-hung Su P-022 Chronic hepatitis B associates with an increased risk of B cell non-Hodgkin’s lymphoma and multiple myeloma
Michelle Ong Chu P-023 Entecavir 0.5 mg versus 1 mg in the treatment of chronic hepatitis B with severe acute exacerbation: a propensity score matching analysis
Takeshi Matsui P-024 The Correlations between HBV Markers in Sera and HBV ccc DNA in Various Disease States
Chih-Lin Lin P-025 The impact of hepatocellular carcinoma development on survival in patients with hepatitis B related cirrhosis receiving antiviral therapy
Hung-Chih Yang P-026 Assessment of host genomic markers associated with long-term control of hepatitis B virus in patients after interferon therapy.
Yuh- Jin Liang P-027 In vivo evidences that Pre-S deletion mutants of hepatitis B virus is more likely to retain in the endoplasmic reticulum than the wild type
Shi Chi Wen P-028 Virological Response and Clinical Events in Patients with Chronic Hepatitis B Treated with Nucleos(t)ide Analogue
Ming Chao Tsai P-029 Comparison of tenofovir and entecavir on the development of acute kidney injury in cirrhotic chronic hepatitis B patient with refractory ascites
Kai-Chi Chang P-030 Tenofovir Treatment in Pregnant Women Prevents Mother-to-Infant Transmission of Hepatitis B Virus by Decreasing Neonatal Viral Exposure
Ming-Lun Yeh P-031 Wisteria floribunda agglutinin-positive Mac-2-binding protein in the prediction of disease severity in chronic hepatitis B patients
Poh-Poo Lim P-032 Dynamic change of quantitative hepatitis B virus surface antigen level during off- treatment follow up in chronic hepatitis B patient.
Haw En Wang P-033 Increase of serum Kallikrein-8 level after long-term telbivudine treatment
Wang-Sheng Ko P-034 Beneficial effects of oligo-fucoidan in patients with chronic hepatitis B virus infection
Yun-Hao Tai P-035 Clinical and Virological Responses of Entecavir and Tenofovir in Chronic Hepatitis B Patients with Liver Decompensation
Tsung-Hui Hu P-036 A comparative study of the effects on bone mineral density and renal toxicity in chronic hepatitis B patients with tenofovir and entecavir
Young-Suk Lim P-037 Impact of HBeAg seroclearance on the risk of HCC development in HBeAg-positive chronic hepatitis B patients treated with entecavir or tenofovir
Mei-hung Pan P-038 Predicting risk of hepatocellular carcinoma for patients with chronic hepatitis B using serum levels of hepatitis B virus DNA splicing
Yi-Cheng Chen P-039 Histological steatosis is not associated with liver fibrosis severity in chronic hepatitis B patients
Po-lin Tseng P-040 Comparisons of the Durability of 6 and 12 months Extended HBV Prophylaxis Antiviral Therapy After Cessation Chemotherapy
TL Ma P-042 The incidence and predictors of retreatment in chronic hepatitis B patients after cessation of entecavir and tenofovir disoproxil fumarate
Yung-Fa Chen P-043 The Eefficacy of Nucleos(t)ide Analogues Treatment for Hepatitis B e Antigen-positive Chronic Hepatitis B Patients under the Guidelines of Taiwan Bureau of National Health Insurance before 2017
Chien-hung Chen P-044 Reactivation of hepatitis B virus in chronic hepatitis B and C coinfected patients treated with direct-acting antiviral treatment
Chang Ping Shen P-045 Health-Related Quality of Life in Chronic Hepatitis B Carriers: A Community-based Study in Northeastern Region of Taiwan
Yu-hua Lan P-046 A Critical Role of CD4 T Cells in IL-21-Mediated Functional Cure of Chronic HBV
Kemal Fariz Kalista P-047 Liver fibrosis regression measured by transient elastography and APRI score among HBV patient treated with antiviral
Yu-An Kan P-048 SUPPLEMENT OF SPIRULINA REDUCES QUANTITATIVE HEPATITIS B SURFACE ANTIGEN IN PATIENTS WITH CHRONIC HEPATITIS B UNDER NUCLEOS(T)IDE ANALOGUES THERAPY - AN OPEN-LABEL, RANDOMIZED CONTROLLED TRIAL
Wei-Yuan Chang P-049 Baseline HBV DNA level predicts the risk of clinical relapse in HBV-infected hematological malignancy patients with Rituximab-containing chemotherapy who stopped prophylactic entecavir therapy
Rachel Wen-juei Jeng P-050 Clinical outcomes in off-Nuc therapy HBeAg negative chronic hepatitis B patients whose EOT HBsAg level >200 IU/ml
Ching-i Huang P-051 The Effect of TDF on the Hepatitis B Virus Eradication
Meng Hsuan Hsieh P-052 The chance of advanced hepatic fibrosis is lower in CHB patients without fatty liver.
Chi-Tan Hu P-053 Characterization of the hepatitis B virus DNA detected in urine of chronic hepatitis B patients